Daily U.S. Stock Market News Briefing (November 12, Tuesday)
Individual Stock News
-
Shell (SHEL.N) won the appeal in the latest emissions ruling in the Netherlands.
-
Astrazeneca (AZN.O) has again raised its revenue and profit expectations for this year.
-
Boeing (BA.N) won an order for 80 737 Max aircraft from Avia Solutions Group.
-
According to the CDE official website, Novartis (NVS.N) plans to include hydrochloride acotiamide tablets for priority review, indicated for reducing the risk of disease progression in adult patients with primary immunoglobulin A nephropathy (IgAN) and proteinuria.
-
Johnson & Johnson (JNJ.N) plans to include nicardipine injection for priority review, applicable for the treatment of patients with generalized myasthenia gravis who are positive for autoantibodies.
-
Morgan Stanley raised the target price for Dell (DELL.N) from $136 to $154, maintaining an "Overweight" rating, citing an increase in sales of the company's AI servers.
-
Tiger Brokers (TIGR.O) announced Q3 results, with revenue of $101 million, a quarter-on-quarter increase of 15.6% and a year-on-year increase of 44.1%, setting a new historical high; the non-GAAP net profit attributable to the parent company was $20.1 million, a quarter-on-quarter increase of 286.5% and a year-on-year increase of 25.6%.
-
Huya (HUYA.N): In Q3 2024, the company's total revenue reached 1.54 billion yuan, with a net profit attributable to the parent company of 78 million yuan. Among them, revenue from game-related services, advertising, and other businesses increased by 209.3% year-on-year to 410 million yuan